ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0142 • ACR Convergence 2025

    Risk Factors for Antiphospholipid Syndrome-associated Nephropathy: A Retrospective Cohort Analysis

    Xiaohan Wei1, Zhixia Yang2, Haoyu Pan2, Yuying Fan2, Jinyi Qian2, Shuyi Yu2 and Hui Shi3, 1Shanghai JiaoTong University, Shanghai, China (People's Republic), 2Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), 3Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)

    Background/Purpose: To identify independent clinical and laboratory risk factors associated with antiphospholipid syndrome-associated nephropathy (APSN) and highlight the clinical importance of early screening in high-risk…
  • Abstract Number: 0140 • ACR Convergence 2025

    Outcome Of Patients With Non-Criteria Manifestations Of Primary Antiphospholipid Syndrome Treated With Immunosuppressants -A Single Centre Study

    Sindhuja Rajendran1, ashish mathew2, sukesh chandran nair3, john mathew2 and ruchika goel2, 1Christian Medical College ,Vellore, Madurai, Tamil Nadu, India, 2Christian Medical college , Vellore , India, Vellore, Tamil Nadu, India, 3Christian,Medical College ,Vellore ,India, Vellore, Tamil Nadu, India

    Background/Purpose: Non-criteria manifestations occur in 24% in Primary antiphospholipid syndrome (PAPS) . The efficacy of immunosuppressants in patients with above condition is not certain due…
  • Abstract Number: 0006 • ACR Convergence 2025

    QEL-005: CD19 CAR-Regulatory T cell therapy, a novel approach for the treatment of complex immune mediated inflammatory diseases including Rheumatoid Arthritis and Systemic Sclerosis

    Jenny McGovern, Georgios Eleftheriadis, Thomas Grothier, Eva Bugallo Blanco, Anna Koi, Mahsa Nemani, Cameron Allum, Emily Hurley, Daniela Penston, Marc Martinez-Llordella, Luke Devey and Nathalie Belmonte, Quell Therapeutics, London, United Kingdom

    Background/Purpose: Rheumatoid Arthritis (RA) and Systemic Sclerosis (SSc) are immune mediated inflammatory diseases (IMID) where a complex interplay of tissue and immune cell activation drives…
  • Abstract Number: 0169 • ACR Convergence 2025

    The High Disease Burden of Connective Tissue Disorder-Interstitial Lung Disease in the USA Demonstrates an Unmet Need for Earlier Diagnosis and Treatment

    Sally Wetten1, George Mu2, Keele E. Wurst3, Roger A. Levy4, Ben Newth5, Svetlana I. Nihtyanova6 and Elaine Irving7, 1GSK, Epidemiology, Stevenage, United Kingdom, 2GSK, Statistics, Collegeville, PA, 3GSK, Immunology and Emerging Epidemiology, Durham, NC, 4GSK, Specialty Care, Global Medical Affairs, Collegeville, PA, 5GSK, Specialty Care, Global Medical Affairs, London, United Kingdom, 6GSK, Clinical Sciences, Research & Development, London, United Kingdom, 7GSK, Clinical, Stevenage, United Kingdom

    Background/Purpose: Interstitial lung disease (ILD) is a serious pulmonary manifestation that can occur across all connective tissue disorders (CTD). Aberrant immune-mediated inflammation and fibrosis leads…
  • Abstract Number: 0112 • ACR Convergence 2025

    Proteome-wide Mendelian Randomization Identifies Therapeutic Targets in Psoriatic Arthritis

    Quan Li1 and Proton Rahman2, 1University of Toronto, Toronto, Canada, 2Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada

    Background/Purpose: While numerous proteins have been linked to psoriatic arthritis (PsA), the causal nature of these associations remains unconfirmed. This study aims to employ a…
  • Abstract Number: 0042 • ACR Convergence 2025

    Serum Proteomic Analysis of Cellular Immune Clusters in Psoriatic Arthritis

    Steven Dang1, Xianwei Li2, Sydney Thib3, Darshini Ganatra4, liqun Diao5, Igor Jurisica6, Vinod Chandran7 and Lihi Eder8, 1Institute of Medical Science, University of Toronto, Toronto, Canada, 2Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, Canada, 3Women’s College Research Institute, Toronto, Canada, 4Gladman Krembil Psoriatic Arthritis Research Program; Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Canada, 5Department of Statistics and Actuarial Science, University of Waterloo, Toronto, Canada, 6University Health Network, Toronto, Canada, 7Division of Rheumatology, Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, and Gladman Krembil Psoriatic Arthritis Research Program, Krembil Research Institute, University Health Network, Toronto, Canada, 8University of Toronto, Toronto, ON, Canada

    Background/Purpose: Our recent study characterized immune endotypes in psoriatic arthritis (PsA) patients using mass cytometry of peripheral blood1. We identified an endotype characterized by high…
  • Abstract Number: 0086 • ACR Convergence 2025

    Androgen Upregulates Interferon Signaling in Osteoclast Differentiation During Inflammatory State

    Kiana Chen1, Chia-Lung Wu2, Gulzada Kulzhanova2 and Homaira Rahimi3, 1University of Rochester School of Medicine and Dentistry, Bronx, NY, 2University of Rochester Medical Center, Rochester, 3University of Rochester, Rochester, NY

    Background/Purpose: Rheumatoid arthritis (RA) is characterized by chronic inflammatory erosions and female predominant disease. Androgen, the dominant sex hormone in males, is protective against bone…
  • Abstract Number: 0032 • ACR Convergence 2025

    Protein Language Model-Guided Homology Identifies Microbial Enzymes Linked to Fibrosis-Prone IgG4-RD and Crohn’s Disease

    Kumar Thurimella1, Ahmed Mohamed2, Chenhao Li3, Tommi Vatanen4, Daniel Graham3, Roisin Owens5, Sabina Leanti La Rosa6, Damian Plichta3, Sergio Bacallado5 and Ramnik Xavier7, 1University of Colorado School of Medicine, Aurora, CO, 2Broad Institute, Boston, 3Broad Institute, Cambridge, MA, 4University of Helsinki, Helsinki, Finland, 5University of Cambridge, Cambridge, United Kingdom, 6NMBU, As, Norway, 7Harvard Medical School, Boston, MA

    Background/Purpose: Uncharacterized microbial enzymes in metagenomics are difficult to annotate, especially in fibrosis-prone conditions like IgG4-related disease (IgG4-RD) and Crohn’s disease (CD), where microbial carbohydrate…
  • Abstract Number: 0065 • ACR Convergence 2025

    Expression and Co-Localization of Malondialdehyde-Acetaldehyde and Citrullinated Proteins in Myocardial Tissues Precedes the Development of Cardiac Fibrosis in Collagen-Induced Arthritis

    Wenxian Zhou1, Hannah Johnson2, Michael Duryee2, Ali Namvaran3, Julian Garcia2, Carlos Hunter2, Tate Johnson2, Daniel Anderson4, Kishore Bidasee2, Geoffrey Thiele2 and Ted Mikuls2, 1University of Nebraska Medical Center, Bellevue, NE, 2University of Nebraska Medical Center, Omaha, NE, 3University of Nebraska Medical Center, Omaha, 40587964, Durham, NC

    Background/Purpose: Patients with rheumatoid arthritis (RA) experience increased morbidity and mortality due to heart failure with preserved ejection fraction (HFpEF), a condition characterized by diastolic…
  • Abstract Number: 0001 • ACR Convergence 2025

    ATG-201, a Novel Steric Hindrance-based Masking CD19xCD3 T-cell Engager (TCE) for the Treatment of B Cell-related Autoimmune Diseases

    Gang Bian1, Tengteng Li1, Huiling Liu2, Zaoshun Hu2, Peng Chen1, Jay Mei3 and Bing Hou3, 1Shanghai Antengene Corporation Limited, Shanghai, China (People's Republic), 2Antengene (Hangzhou) Biologics, Hangzhou, Zhejiang, China (People's Republic), 3Antengene Corporation, Shanghai, China (People's Republic)

    Background/Purpose: CD19-targeted therapies, such as chimeric antigen receptor (CAR)-T or T-cell engagers (TCE), have been approved for the treatment of B cell malignancies. By depleting…
  • Abstract Number: 0187 • ACR Convergence 2025

    Message Testing in Online Recruitment Advertisements for a National Rheumatoid and Psoriatic Arthritis Study

    Matthew Kearney1, Sarah Hopkins Gillespie1, Stephanie Chen1, Tyler Cavin2, Christine Lindsay3, Christopher Ritchlin4, Jennifer Seifert5, Susan Goodman6, Jessica Fishman1 and Alexis Ogdie7, 1University of Pennsylvania, Philadelphia, PA, 2University of Rochester, Rochester, NY, 3Self, prosper, TX, 4University of Rochester Medical Center, Canandaigua, NY, 5University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, 6Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 7Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE

    Background/Purpose: Study recruitment procedures have increasingly included paid advertisements using social media. However, it is unclear which types of message framing will be the most…
  • Abstract Number: 0196 • ACR Convergence 2025

    Increasing Timely Rheumatology Evaluation for High Risk Lupus Patients

    Steven Taylor1 and Elena Weinstein2, 1University of Colorado, Denver, CO, 2University of Colorado, Englewood, CO

    Background/Purpose: The rheumatology workforce shortage presents many challenges to the delivery of rheumatology care. Improving timely access to rheumatology for patients with life or organ…
  • Abstract Number: 0054 • ACR Convergence 2025

    Microbial Cues Promote Arthritis and Alter T Cell Selection in SKG Mice

    Astha Patel1, Steven yu1, Yuka Nakao1, Mohana Mukherjee1, Diego Orellana2, Jose Scher3, Peter Turnbaugh1, Renuka Nayak4 and Judith Ashouri1, 1University of California, San Francisco, San Francisco, CA, 2University of California San Francisco, San Francisco, CA, 3New York University School of Medicine, New York, NY, 4University of California, San Francisco (UCSF), San Francisco, CA

    Background/Purpose: Dysbiosis of the gut microbiota has been linked to rheumatoid arthritis (RA), but it remains unclear whether these microbial alterations are causal or secondary…
  • Abstract Number: 0185 • ACR Convergence 2025

    Promoting Health Services Research Rigor and Reproducibility using CodeMapper: A novel tool for harmonization, collaboration, and precision

    Emily Holladay1, Nick McCormick2, Robert Matthews3, Shanette Daigle4, Fenglong Xie5, Tapan Mehta1 and Jeffrey Curtis6, 1University of Alabama at Birmingham, Birmingham, AL, 2Auburn University, Auburn, AL, 3Foundation for Advancing Science Technology Education and Research, Hoover, 4Foundation for Advancing Science, Technology, Education and Research (FASTER), Hoover, AL, 5The University of Alabama at Birmingham, Birmingham, AL, 6Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL

    Background/Purpose: Medication, procedure, and diagnosis coding using structured data is fundamental to using real-world data to support clinical research, impacting cohort selection, patient recruitment, and…
  • Abstract Number: 0124 • ACR Convergence 2025

    Single-cell atlas reveals the central-and-peripheral immune remodeling mechanism and clinical benefits of talitacicept therapy in patients with primary antiphospholipid syndrome

    Haoyu Pan1, Shiyan Gu1, Xiaohan Wei2, Yuying Fan1, Jinyi Qian1, Shuyi Yu1 and Hui Shi3, 1Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), 2Shanghai JiaoTong University, Shanghai, China (People's Republic), 3Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)

    Background/Purpose: To elucidate the molecular and cellular mechanisms underlying Talitacicept therapy in primary antiphospholipid syndrome (PAPS) patients using integrated single-cell RNA and TCR/BCR profiling of…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 2605
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology